Selective Degradation of MLK3 by a Novel CEP1347-VHL-02 PROTAC Compound Limits the Oncogenic Potential of TNBC-Reference-Cited by-同舟云学术

Selective Degradation of MLK3 by a Novel CEP1347-VHL-02 PROTAC Compound Limits the Oncogenic Potential of TNBC

Published:2024-08-29 Issue:17 Volume:67 Page:15012-15028
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Karpińska Kamila¹,Mehlich Dawid¹²,Sabbasani Venkata R.³^ORCID,Łomiak Michał¹,Torres-Ayuso Pedro⁴,Wróbel Katarzyna¹,Truong Vi Nguyen-Phuong¹,Serwa Remigiusz⁵,Swenson Rolf E.³,Brognard John²,Marusiak Anna A.¹^ORCID

Affiliation:

1. Laboratory of Molecular OncoSignalling, IMol Polish Academy of Sciences, Warsaw 02-247, Poland

2. Laboratory of Cell and Developmental Signaling, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States

3. Chemistry and Synthesis Center, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, United States

4. Department of Cancer and Cellular Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania 19140, United States

5. Proteomic Core Facility, IMol Polish Academy of Sciences, Warsaw 02-247, Poland

Funder

Narodowa Agencja Wymiany Akademickiej

National Cancer Institute

Narodowe Centrum Nauki

Polsko-Amerykanska Komisja Fulbrighta

Intramural Research Program

Fox Chase Cancer Center

Temple University

National Institutes of Health

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00577

Reference47 articles.

1. Mixed-lineage kinase control of JNK and p38 MAPK pathways

2. MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation

3. Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors

4. Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein

5. The role of mixed lineage kinase 3 (MLK3) in cancers